Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.54 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.49 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29998893 | 0.84 | CYP2A6 (0.46) | TRPV4CYP11B2CYP11B1S1PR3VCAM1 | |
| SCHEMBL481131 | 0.84 | CYP2A6 (0.46) | TRPV4CYP11B2CYP11B1S1PR3VCAM1 | |
| SCHEMBL34472232 | 0.84 | CYP11B2 (0.66) | TRPV4CYP11B2CYP11B1S1PR3 | |
| SCHEMBL22563047 | 0.82 | EGFR (0.46) | TRPV4CYP11B2CYP11B1S1PR3S1PR1 | |
| SCHEMBL3480466 | 0.80 | CYP11B2 (0.54) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL31441456 | 0.78 | MAOA (0.61) | TRPV4VCAM1MAOAMAOBCYP2A6 | |
| SCHEMBL7050401 | 0.78 | MAOA (0.61) | TRPV4VCAM1MAOAMAOBCYP2A6 | |
| SCHEMBL9996715 | 0.77 | CYP11B1 (0.35) | TRPV4CYP11B2CYP11B1S1PR3VCAM1 | |
| SCHEMBL3433277 | 0.77 | KMT2A (0.36) | TRPV4CYP11B2CYP11B1S1PR3VCAM1 | |
| SCHEMBL29932195 | 0.77 | KMT2A (0.36) | TRPV4CYP11B2CYP11B1S1PR3VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110302733-B | Preparation method of double-halogen nitrogen-containing heterocyclic compound | 北京六合宁远科技有限公司 | 2021-07-30 | — | — | CN | claimed |
| US-9039919-B2 | Gel-type polymer electrolyte for dye-sensitized solar cell and dye-sensitized solar cell comprising the same | Research & Business Foundation Sungkyunkwan University (KR) | 2015-05-26 | — | — | US | claimed |
| US-20130330873-A1 | GEL-TYPE POLYMER ELECTROLYTE FOR DYE-SENSITIZED SOLAR CELL AND DYE-SENSITIZED SOLAR CELL COMPRISING THE SAME | Research & Business Foundation Sungkyunkwan University (KR) | 2013-12-12 | — | — | US | claimed |
| US-8257871-B2 | a mixture of cyclic esters, a nitrile-containing solvent and lithium salts, for use in rechargeable batteries, to improve swelling characteristics, discharge capacity characteristics at low temperatures and durability | SAMSUNG SDI CO., LTD. (KR) | 2012-09-04 | — | — | US | claimed |
| US-7718322-B2 | Electrolyte for rechargeable lithium battery and rechargeable lithium battery comprising same | SAMSUNG SDI CO., LTD. (KR) | 2010-05-18 | — | — | US | claimed |
| US-20080131785-A1 | Electrolyte for lithium secondary battery and lithium secondary battery including the same | SAMSUNG SDI CO., LTD., A CORPORATION CHARTERED IN AND EXISTING UNDER THE LAWS OF THE REPUBLIC OF KOREA (KR) | 2008-06-05 | — | — | US | claimed |
| EP-1508934-B1 | Electrolyte for rechargeable lithium battery and rechargeable lithium battery comprising the same | SAMSUNG SDI CO LTD (KR) | 2007-02-28 | — | — | EP | claimed |
| US-20050084765-A1 | Electrolyte for rechargeable lithium battery and rechargeable lithium battery comprising same | SAMSUNG SDI CO., LTD. (KR) | 2005-04-21 | — | — | US | claimed |
| EP-1508934-A1 | Electrolyte for rechargeable lithium battery and rechargeable lithium battery comprising the same | Samsung SDI Co., Ltd. (KR) | 2005-02-23 | — | — | EP | claimed |
| CN-122071471-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-22 | — | — | CN | disclosed |
| CN-122010945-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| CN-122010946-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| US-12540130-B2 | Substituted pyrrolidine amides IV | GRUENENTHAL GMBH (DE) | 2026-02-03 | — | — | US | disclosed |
| US-12534471-B2 | Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-27 | — | — | US | disclosed |
| US-4379932-A | Process for preparing spiro[indoline-3,4'-piperidine]s | AMERICAN HOECHST CORPORATION (US) | 1983-04-12 | — | — | US | disclosed |
| US-4379933-A | Process for preparing spiro[indoline-3,4'-piperidine]s | AMERICAN HOECHST CORPORATION (US) | 1983-04-12 | — | — | US | disclosed |
| US-4345081-A | Spiro[indoline-3,4'-piperidine]s | AMERICAN HOECHST CORPORATION (US) | 1982-08-17 | — | — | US | disclosed |
| US-4307235-A | Spiro[indoline-3,4'-piperidine]s | AMERICAN HOECHST CORPORATION (US) | 1981-12-22 | — | — | US | disclosed |
| US-4209625-A | Spiro[indoline-3,4'-piperidine]s | AMERICAN HOECHST CORPORATION (US) | 1980-06-24 | — | — | US | disclosed |
| US-3966728-A | ANTIPEPTIC ULCER ACTIVITY | NIPPON SHINYAKU CO., LTD. (JA) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540130-B2 | Substituted pyrrolidine amides IV | NR3C1, NR3C2, CRHR1 | TRPV4 1742/4885CYP11B2 13/4885CYP11B1 7/4885 |
| US-12534471-B2 | Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof | HCRTR2, HCRTR1, NPY1R | TRPV4 676/4885CYP11B2 457/4885CYP11B1 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.